Literature DB >> 7876138

Effect of caldesmon on the assembly of smooth muscle myosin.

E Katayama1, G Scott-Woo, M Ikebe.   

Abstract

Smooth muscle myosin filaments are much less stable than the skeletal muscle counterpart. Smooth myosin requires higher concentration of Mg2+ than skeletal myosin to form thick filaments and addition of ATP disassembles the dephosphorylated smooth muscle myosin filaments into monomers but not phosphorylated ones. We found that the addition of caldesmon to dephosphorylated myosin induced the formation of the filaments under the conditions where myosin by itself is soluble or disassembled. Although the induced filaments were short at 1 mM Mg2+, they became medium sized and seemed like side polar filaments with prominent 14 nm periodicity at higher Mg2+ conditions (8 mM). In the presence of F-actin, myosin filaments induced by caldesmon were associated along actin filaments to form large structures. The association of actin and myosin filaments was observed only in the presence of caldesmon, suggesting that caldesmon cross-linked actin and myosin filaments. This cross-linking was disrupted by the addition of calmodulin. Caldesmon-induced filament formation of dephosphorylated myosin in the presence of Mg(2+)-ATP may explain the existence of myosin filaments in relaxed smooth muscle fibers. A similar effect of telokin on myosin filament assembly was also examined and is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876138     DOI: 10.1074/jbc.270.8.3919

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Myosin filaments in smooth muscle cells do not have a constant length.

Authors:  Jeffrey C-Y Liu; Jörg Rottler; Lu Wang; Jenny Zhang; Chris D Pascoe; Bo Lan; Brandon A Norris; Ana M Herrera; Peter D Paré; Chun Y Seow
Journal:  J Physiol       Date:  2013-09-30       Impact factor: 5.182

2.  Both N-terminal myosin-binding and C-terminal actin-binding sites on smooth muscle caldesmon are required for caldesmon-mediated inhibition of actin filament velocity.

Authors:  Z Wang; H Jiang; Z Q Yang; S Chacko
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  Affinity and structure of complexes of tropomyosin and caldesmon domains.

Authors:  E J Hnath; C L Wang; P A Huber; S B Marston; G N Phillips
Journal:  Biophys J       Date:  1996-10       Impact factor: 4.033

4.  Polymerization of myosin on activation of rat anococcygeus smooth muscle.

Authors:  J Q Xu; J M Gillis; R Craig
Journal:  J Muscle Res Cell Motil       Date:  1997-06       Impact factor: 2.698

5.  Multiscale and Multiaxial Mechanics of Vascular Smooth Muscle.

Authors:  Sae-Ii Murtada; Jay D Humphrey; Gerhard A Holzapfel
Journal:  Biophys J       Date:  2017-08-08       Impact factor: 4.033

Review 6.  Regulation of myosin light chain kinase and telokin expression in smooth muscle tissues.

Authors:  B Paul Herring; Omar El-Mounayri; Patricia J Gallagher; Feng Yin; Jiliang Zhou
Journal:  Am J Physiol Cell Physiol       Date:  2006-06-14       Impact factor: 4.249

7.  Location of smooth-muscle myosin and tropomyosin binding sites in the C-terminal 288 residues of human caldesmon.

Authors:  P A Huber; I D Fraser; S B Marston
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

8.  Telokin mediates Ca2+-desensitization through activation of myosin phosphatase in phasic and tonic smooth muscle.

Authors:  Nandini Choudhury; Alexander S Khromov; Andrew P Somlyo; Avril V Somlyo
Journal:  J Muscle Res Cell Motil       Date:  2005-02-24       Impact factor: 2.698

9.  Mode of caldesmon binding to smooth muscle thin filament: possible projection of the amino-terminal of caldesmon from native thin filament.

Authors:  E Katayama; M Ikebe
Journal:  Biophys J       Date:  1995-06       Impact factor: 4.033

10.  Identification and localization of caldesmon in cardiac muscle.

Authors:  G C Scott-Woo; M P Walsh; M Ikebe; G J Kargacin
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.